Bellerophon Therapeutics Forms Scientific Advisory Board

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bellerophon Therapeutics Forms Scientific Advisory Board for INOpulse(R) Programs

HAMPTON, N.J., May 7, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH ), a clinical-stage biotherapeutics company, today announced the formation of an INOpulse ® Scientific Advisory Board (SAB) comprised of internationally renowned experts in pulmonary hypertension (PH). The SAB will work closely with Bellerophon's medical team as the Company prepares to advance the development of its proprietary inhaled nitric oxide drug-device combination technology across a range of potential indications for patients affected by PH.

"Creation of the INOpulse Scientific Advisory Board underscores our commitment to the development of our technology in pulmonary hypertension for chronic outpatient use to benefit patients with various forms of this debilitating disease," said Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon. "We are especially pleased to have such a distinguished group of thought leaders working with us to broaden and advance our programs in PH. The participation of these distinguished SAB members reflects the advances we have made in our clinical programs in the past year, and will help us define and advance our programs in the next few years."

Members of the INOpulse Scientific Advisory Board are:

  • Greg Elliot, M.D., MACP, Medical Director of the Pulmonary Hypertension Center and Chairman of the Department of Medicine at Intermountain Medical Center and Professor of Medicine at the University of Utah
  • Nazzareno Galie, M.D., Head of the Pulmonary Hypertension Center at the University of Bologna
  • Ardeschir Ghofrani, M.D., Associate Professor for Internal Medicine and Head of the Pulmonary Hypertension Division at University Hospital, Giessen
  • Fernando Martinez, M.D., Executive Vice Chair of Medicine at the Weill Cornell Medical College and New York-Presbyterian Hospital/Weill Cornell Medical Center
  • Vallerie McLaughlin, M.D., Professor of Medicine and Director of the Pulmonary Hypertension Program at the University of Michigan; Attending Physician at the University of Michigan Health System in Ann Arbor, Michigan
  • Robert Naeije, M.D., Ph.D, Professor and Chairman of the Department of Physiology and Pathophysiology at Erasme University Hospital, Brussels
  • Steve Rennard, M.D., Larson Professor of Medicine in the Pulmonary and Critical Care Medicine, Department of Internal Medicine at the University of Nebraska Medical Center in Omaha
  • Lewis Rubin, M.D., FACP, FCCP, FAHA, FRCP, Emeritus Professor of Medicine and Emeritus Director of Pulmonary and Critical Care at the University of California in San Diego
  • Olivier Sitbon, M.D., Ph.D., Professor of Respiratory Medicine at the South Paris University

About INOpulse

INOpulse is Bellerophon's proprietary pulsatile nitric oxide drug-device combination technology for the treatment of pulmonary hypertension in the chronic outpatient setting. Two of the Company's programs using this technology are currently in development – one for the treatment of PAH is expected to begin Phase 3 trials later this year, and a second for the treatment of PH-COPD is being evaluated for a Phase 2b trial.

Nitric oxide is naturally produced and released by portions of the blood vessels and results in smooth muscle relaxation. In particular, nitric oxide controls muscle tone in blood vessels and, thus, is an important factor in regulating blood pressure. As the muscles of the blood vessels relax, blood flow increases, helping the heart to deliver more blood to the body. Bellerophon Therapeutics is evaluating the effect of nitric oxide when administered by inhalation, as a pulsed dose, to the alveoli of the lungs. The Company expects inhaled nitric oxide, delivered using the INOpulse device, to act in a similar manner to naturally produced nitric oxide with minimal effects on blood pressure outside of the lungs, an important safety consideration. Bellerophon acquired exclusive worldwide rights to develop and commercialize INOpulse in PAH, PH-COPD and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) from Ikaria, now a part of Mallinckrodt Plc. Bellerophon is also evaluating the potential use of INOpulse for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and PH associated with Sarcoidosis, subject to finalizing discussions and entering into an agreement for additional licensing rights from Mallinckrodt.

About Bellerophon

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse, one for the treatment of pulmonary arterial hypertension (PAH) and a second for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). Bellerophon's third product candidate is bioabsorbable cardiac matrix (BCM), which is an injectable device currently undergoing a trial for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (AMI), commonly known as a heart attack. This trial, which is expected to report results in mid-2015, is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in the United States. Bellerophon has an exclusive worldwide license to BCM from BioLineRx Ltd. For more information, visit www.bellerophon.com .

Forward-looking Statements

Any statements in this press release about Bellerophon's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Bellerophon's views only as of the date of this press release. Bellerophon anticipates that subsequent events and developments will cause its views to change. While Bellerophon may elect to update these forward-looking statements at some point in the future, Bellerophon specifically disclaims any obligation to do so.

At Bellerophon: Manesh Naidu, Chief Business Officer (908) 574-4770 At Rx Communications Group: Paula Schwartz (Investors) (917) 322-2216 Eric Goldman (Media) (917) 322-2563

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 46

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 138

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 136

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 123

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 85

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 118

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading

Top 5 Most Recently Viewed Articles

Wicked Cutz, Cinnabon Team Up for Bacon Jerky Debut

Updated Category News Views 13

Ever thought you'd see the day when your protein snack could taste like a cinnamon roll? Well, folks, that day has arrived. Wicked Cutz, a force in the meat snack industry, and Cinnabon, the undisputed champs of cinnamon rolls, have rolled out a product that's bound to raise some eyebrows: bacon jerky with a sweet pastry twist. Why Bacon Jerky? You might be wondering, why...

Continue Reading
10 High-Yielding Small-Cap Stocks Under $15 in 2024

Updated Category Stocks Views 542

In the ever-evolving landscape of the stock market, small-cap stocks can be a gold mine for investors seeking high yields without breaking the bank. As we navigate through 2024, let's delve into a curated list of 10 small-cap stocks trading under $15 that offer attractive dividend yields. But remember, high yields can be as enticing as they are perilous, so tread with...

Continue Reading
Frazier Life Sciences Secures Over $630M for Growth Initiatives

Updated Category News Views 239

Frazier Life Sciences (FLS) raised over $630 million back in 2024, which got everyone buzzing on the trading floor. This wasn't just pocket change; it came from an oversubscribed fundraise that saw new and existing investors jumping on board like it was Black Friday. Talk about a cash infusion! The Public Fund has amassed around $1.7 billion since its launch three years...

Continue Reading
1847 Holdings LLC Achieves Milestone with $11.1M Offering

Updated Category News Views 112

1847 Holdings LLC Successfully Completes Public Offering 1847 Holdings LLC (NYSE American: EFSH), a company dedicated to investing in high-potential middle-market businesses, recently announced an exciting achievement. The firm has successfully closed its public offering, resulting in gross proceeds of $11.1 million. This accomplishment reflects the company's continued...

Continue Reading
Live Nation Entertainment's Stock Analysis Amid Sell-Off

Updated Category News Views 238

Understanding Live Nation Entertainment's Recent Stock Movements The trading landscape for Live Nation Entertainment, Inc. (LYV) has seen quieter activity following a significant sell-off of 6.5%. Investors and market analysts are closely observing whether this stock will continue its downward trajectory. Technical Analysis: Support and Resistance Levels Identifying Key...

Continue Reading